thiotepa

Summary

Summary: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).

Top Publications

  1. Montemurro M, Kiefer T, Schuler F, Al Ali H, Wolf H, Herbst R, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-. Ann Oncol. 2007;18:665-71 pubmed
    ..the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain ..
  2. Mondie C, Vandergrift K, Wilson C, Gulinello M, Weber E. The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors in mice. Behav Brain Res. 2010;209:66-72 pubmed publisher
    b>ThioTEPA is a chemotherapeutic agent used in the treatment of cancers, and more recently has been proposed as a component of high-dose therapy for young patients with recurrent malignant brain tumors...
  3. Bengala C, Pazzagli I, Innocenti F, Donati S, Favre C, Menconi M, et al. High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). Ann Oncol. 2001;12:69-74 pubmed
    ..After six courses of epirubicin-paclitaxel +/- gemcitabine patients received a course of thiotepa 600 mg/m2 + melphalan 160 mg/m2 with hemopoietic support...
  4. Huitema A, Mathot R, Tibben M, Rodenhuis S, Beijnen J. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. J Pharmacokinet Pharmacodyn. 2001;28:211-30 pubmed
    Cyclophosphamide (CP) is widely used in high-dose chemotherapy regimens in combination with thioTEPA. CP is a prodrug and is activated by cytochrome P450 to 4-hydroxycyclophosphamide (HCP) which yields the final cytotoxic metabolite ..
  5. Huitema A, Tibben M, Kerbusch T, Zwikker J, Rodenhuis S, Beijnen J. Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. J Chromatogr B Biomed Sci Appl. 1998;716:177-86 pubmed
    A sensitive assay for the simultaneous determination of N,N',N"-triethylenethiophosphoramide (thioTEPA), its metabolite N,N',N"-triethylenephosphoramide (TEPA), cyclophosphamide (CP) and its metabolite 2-..
  6. Shukla N, Kobos R, Renaud T, Steinherz L, Steinherz P. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. Pediatr Blood Cancer. 2014;61:431-5 pubmed publisher
    ..5 days, topotecan 1 mg/m(2) /day IV continuous infusion × 5 days, vinorelbine 20 mg/m(2) /week IV × 3 weeks, thiotepa 15 mg/m(2)/day IV × 1 day)...
  7. Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquieres H, et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica. 2012;97:1751-6 pubmed publisher
  8. Rodenhuis S, Bontenbal M, Beex L, Wagstaff J, Richel D, Nooij M, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003;349:7-16 pubmed
    ..except that high-dose chemotherapy (6 g of cyclophosphamide per square meter of body-surface area, 480 mg of thiotepa per square meter, and 1600 mg of carboplatin per square meter) with autologous peripheral-blood hematopoietic ..
  9. Tallman M, Gray R, Robert N, LeMaistre C, Osborne C, Vaughan W, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349:17-26 pubmed
    ..fluorouracil (CAF) or the same adjuvant chemotherapy followed by high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation...

More Information

Publications70

  1. Mignone R, Weber E. Potent inhibition of cell proliferation in the hippocampal dentate gyrus of mice by the chemotherapeutic drug thioTEPA. Brain Res. 2006;1111:26-9 pubmed
    ..We have examined whether several such drugs capable of penetrating the blood-brain barrier - thioTEPA and 5-fluorouracil - influence the normal process of cell proliferation underlying neurogenesis in the dentate ..
  2. Hiwarkar P, Arkenau H, Treleaven J, Morgan G, Potter M, Ethell M. The feasibility of using topotecan, vinorelbine, thiotepa and gemcitabine (TVTG) in adult patients with relapsed/refractory acute lymphoblastic leukaemia/lymphoma. Leukemia. 2008;22:1627-9 pubmed publisher
  3. Martinoni A, Cipolla C, Cardinale D, Civelli M, Lamantia G, Colleoni M, et al. Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa. Chest. 2004;126:1412-6 pubmed
    ..This study was performed in order to investigate the long-term effects of intracavitary treatment with thiotepa in the reduction of pericardial effusion (PE) recurrences. Prospective controlled intervention study...
  4. Massimino M, Gandola L, Luksch R, Spreafico F, Riva D, Solero C, et al. Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol. 2005;7:41-8 pubmed
    ..Our study protocol incorporated sequential chemotherapy and high-dose thiotepa in the preradiant phase, followed by focal radiotherapy and maintenance with vincristine and lomustine for a ..
  5. Huitema A, Spaander M, Mathĵt R, Tibben M, Holtkamp M, Beijnen J, et al. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol. 2002;13:374-84 pubmed
    ..The aim of this study was to establish the pharmacokinetics of cyclophosphamide, thiotepa, carboplatin and all relevant metabolites in a widely used high-dose combination and to study possible ..
  6. Gilheeney S, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel I. Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatr Blood Cancer. 2010;54:591-5 pubmed publisher
    b>Thiotepa and carboplatin are known to be active in central nervous system tumors. Topotecan potentiates the anti-cancer effects of alkylators and crosses the blood-brain barrier...
  7. Kobune M, Xu Y, Baum C, Kelley M, Williams D. Retrovirus-mediated expression of the base excision repair proteins, formamidopyrimidine DNA glycosylase or human oxoguanine DNA glycosylase, protects hematopoietic cells from N,N',N"-triethylenethiophosphoramide (thioTEPA)-induced toxicity in v. Cancer Res. 2001;61:5116-25 pubmed
    ..N,N',N"-Triethylenethiophosphoramide (thioTEPA) induces the formation of amino-ethyl adducts of guanine, resulting in imidazole ring opening [..
  8. O Dwyer P, LaCreta F, Engstrom P, Peter R, Tartaglia L, Cole D, et al. Phase I/pharmacokinetic reevaluation of thioTEPA. Cancer Res. 1991;51:3171-6 pubmed
    Because the initial evaluation of N,N',N''-triethylenethiophosphoramide (thioTEPA) preceded the standardized approach to the Phase I trials, uncertainty surrounds the recommended dose...
  9. Huitema A, Mathot R, Tibben M, Schellens J, Rodenhuis S, Beijnen J. Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. Br J Clin Pharmacol. 2001;51:61-70 pubmed
    To study the population pharmacokinetics of thioTEPA and its main metabolite TEPA in patients receiving high-dose chemotherapy consisting of thioTEPA (80-120 mg x m(-2) x day(-1)), cyclophosphamide (1000-1500 mg x m(-2) x day(-1)) and ..
  10. van Warmerdam L, Rodenhuis S, van der Wall E, Maes R, Beijnen J. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer. 1996;73:979-84 pubmed
    ..in patients treated with high dose carboplatin (400 mg m-2 day-1), cyclophosphamide (1500 mg m-2 day-1) and thiotepa (120 mg m-2 day-1) for four consecutive days, followed by peripheral stem cell transplantation...
  11. Stadtmauer E, O NEILL A, Goldstein L, Crilley P, Mangan K, Ingle J, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 2000;342:1069-76 pubmed
    ..chemotherapy were then randomly assigned to receive either a single course of high doses of carboplatin, thiotepa, and cyclophosphamide plus transplantation of autologous hematopoietic stem cells or up to 24 cycles of ..
  12. Gilman A, Jacobsen C, Bunin N, Levine J, Goldman F, Bendel A, et al. Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a Pediatric Blood and MarrowTransplant Consortium study. Pediatr Blood Cancer. 2011;57:506-13 pubmed publisher
    ..Two cycles of HDC/SCR were given. Cycle 1 included thiotepa and carmustine given on days -5, -4, and -3...
  13. Biron P, Durand M, Roche H, Delozier T, Battista C, Fargeot P, et al. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant. 2008;41:555-62 pubmed
    ..Patients with objective response (N=179) were randomized to one cycle of HDC (cyclophosphamide 6000 mg/m(2) and thiotepa 800 mg/m(2) (CHUT)) and stem cell support (N=88), or no further treatment (N=91)...
  14. Shapiro C, Ayash L, Webb I, Gelman R, Keating J, Williams L, et al. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol. 1997;15:674-83 pubmed
    As an alternative to single-cycle cyclophosphamide, thiotepa, and carboplatin (CTCb) intensification, we evaluated the feasibility of administering one-quarter dose CTCb for four cycles with peripheral-blood progenitor-cell (PBPC) and ..
  15. Colleoni M, Martinelli G, Beretta F, Marone C, Gallino A, Fontana M, et al. Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen. J Clin Oncol. 1998;16:2371-6 pubmed
    ..Patients with malignant pericardial effusions were treated with intracavitary thiotepa (15 mg on days 1, 3, and 5) through an indwelling pericardial cannula after extraction of as much pericardial ..
  16. Cheng T, Forsyth P, Chaudhry A, Morris D, Gluck S, Russell J, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant. 2003;31:679-85 pubmed
    ..upon these dismal results, we treated seven PCNSL patients with HD-MTX-based induction therapy followed by thiotepa, busulfan, cyclophosphamide (TBC), and autologous stem cell transplant (ASCT), without WBRT...
  17. Schrama J, Baars J, Holtkamp M, Schornagel J, Beijnen J, Rodenhuis S. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Bone Marrow Transplant. 2001;28:173-80 pubmed
    ..was to determine the feasibility and efficacy of multiple courses of high-dose cyclophosphamide, carboplatin and thiotepa with peripheral blood progenitor cell (PBPC) transplantation in women with advanced breast cancer...
  18. Hawkins D, Barnett T, Bensinger W, Gooley T, Sanders J. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol. 2000;34:328-37 pubmed
    ..All patients received busulfan, melphalan, and thiotepa (BuMelTT) as chemotherapy conditioning...
  19. Ekhart C, Doodeman V, Rodenhuis S, Smits P, Beijnen J, Huitema A. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol. 2009;67:50-60 pubmed publisher
    b>Thiotepa is widely used in high-dose chemotherapy. Previous studies have shown relations between exposure and severe organ toxicity. Thiotepa is metabolized by cytochrome P450 and glutathione S-transferase enzymes...
  20. Raiola A, Van Lint M, Lamparelli T, Gualandi F, Mordini N, Berisso G, et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol. 2000;109:716-21 pubmed
    ..The regimen consisted of thiotepa (THIO; 10 mg/kg) on day -5 and cyclophosphamide (CY; 50 mg/kg) on days -3 and -2 (total dose 100 mg/kg)...
  21. de Jonge M, Huitema A, Holtkamp M, van Dam S, Beijnen J, Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol. 2005;56:370-8 pubmed
    Patients receiving the highly emetogenic high-dose chemotherapy regimen with cyclophosphamide, thiotepa and carboplatin (CTC) may benefit from the neurokin-1 receptor antagonist aprepitant in addition to standard anti-emetic therapy...
  22. Dunkel I, Boyett J, Yates A, Rosenblum M, Garvin J, Bostrom B, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol. 1998;16:222-8 pubmed
    ..Very few patients survive with conventional treatment. This study evaluated the use of high-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue (ASCR) in patients with recurrent medulloblastoma...
  23. Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, et al. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epiru. J Clin Oncol. 2003;21:3659-64 pubmed
    ..courses versus induction FEC therapy for three courses followed by high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin (CTCb) supported by peripheral-blood stem cells...
  24. Kolb E, Steinherz P. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia. 2003;17:1967-72 pubmed
    ..28 patients with multiple relapsed or refractory acute leukemia received a combination of topotecan, vinorelbine, thiotepa, dexamethasone, and, for patients with an M3 marrow on day 7, gemcitabine...
  25. Li F, Patterson A, Höfer C, Krausz K, Gonzalez F, Idle J. A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics. Biochem Pharmacol. 2011;81:1043-53 pubmed publisher
    b>ThioTEPA, an alkylating agent with anti-tumor activity, has been used as an effective anticancer drug since the 1950s...
  26. Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol. 2012;23:2670-5 pubmed
    ..We report long-term data of patients who were treated according to HCT-ASCT containing protocols...
  27. de Jonge M, Huitema A, Rodenhuis S, Beijnen J. Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. J Pharmacokinet Pharmacodyn. 2004;31:135-56 pubmed
    Cyclophosphamide (CP) and thiotepa (TT) are frequently administered simultaneously in high-dose chemotherapy regimens...
  28. Huitema A, Mathot R, Tibben M, Rodenhuis S, Beijnen J. Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen. Ther Drug Monit. 2001;23:650-7 pubmed
    b>Thiotepa is an alkylating agent widely used in high-dose chemotherapy...
  29. Majolino I, Davoli M, Carnevalli E, Locasciulli A, Di Bartolomeo P, Scimè R, et al. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma. 2007;48:759-66 pubmed
    ..The thiotepa, fludarabine, and melphalan conditioning regimen can produce remissions in the majority of MM patients with a ..
  30. van der Wall E, Nooijen W, Baars J, Holtkamp M, Schorangel J, Richel D, et al. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer. 1995;71:857-62 pubmed
    ..in 26 patients; 28 patients subsequently underwent high-dose chemotherapy consisting of carboplatin 1600 mg m-2, thiotepa 480 mg m-2 and cyclophosphamide 6 g m-2 (CTC) followed by PBSC transplantation...
  31. Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004;100:2607-12 pubmed
    ..the authors compared the outcomes associated with high-dose melphalan (HDM) and a more intensive regimen of thiotepa, busulfan, and cyclophosphamide (TBC) in patients with multiple myeloma...
  32. Rosenfeld A, Kletzel M, Duerst R, Jacobsohn D, Haut P, Weinstein J, et al. A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors. J Neurooncol. 2010;97:247-55 pubmed publisher
    ..Cytoreduction regimen #1 consisted of carboplatin (500 mg/m(2)) x 3 days, etoposide (250 mg/m(2)) x 3 days, and thiotepa (300 mg/m(2)) x 3 days...
  33. Barek J, Cvacka J, De Meo M, Laget M, Michelon J, Castegnaro M. Chemical degradation of wastes of antineoplastic agents amsacrine, azathioprine, asparaginase and thiotepa. Ann Occup Hyg. 1998;42:259-66 pubmed
    ..H2O2, 30%), were tested for the degradation of four anticancer drugs: Amsacrine, Azathioprine, Asparaginase and Thiotepa. The efficiency of the degradation was monitored by high-performance liquid chromatography...
  34. Rodenhuis S, Richel D, van der Wall E, Schornagel J, Baars J, Koning C, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998;352:515-21 pubmed
    ..This high-dose regimen comprised cyclophosphamide 6 g/m2, thiotepa 480 mg/m2, and carboplatin 1600 mg/m2. The primary endpoint was overall and disease-free survival...
  35. Jacobson P, Green K, Birnbaum A, Remmel R. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol. 2002;49:461-7 pubmed
    To establish the cytochrome P450 (CYP) isozymes involved in the metabolism of the alkylating agent, thiotepa, to the pharmacologically active metabolite, TEPA...
  36. Musser S, Pan S, Callery P. Liquid chromatography-thermospray mass spectrometry of DNA adducts formed with mitomycin C, porfiromycin and thiotepa. J Chromatogr. 1989;474:197-207 pubmed
    ..for the analysis of DNA adducts formed from the interaction of the anticancer drugs mitomycin C, porfiromycin and thiotepa with calf thymus DNA...
  37. Ekhart C, Rodenhuis S, Smits P, Beijnen J, Huitema A. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics. 2008;18:1009-15 pubmed publisher
    High-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin (CTC) has been developed as a possible curative treatment modality in several solid tumours...
  38. Modak S, Gardner S, Dunkel I, Balmaceda C, Rosenblum M, Miller D, et al. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol. 2004;22:1934-43 pubmed
    ..relapse or progression despite having received initial chemotherapy and/or radiotherapy were treated with thiotepa-based HDC regimens followed by ASCR...
  39. Walsky R, Obach R. A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab Dispos. 2007;35:2053-9 pubmed
    ..CYP2B6 and compare this selectivity versus other CYP2B6 inactivators: 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine. Values of K(I) and k(inact) for PPP were 5.6 microM and 0...
  40. de Jonge M, Huitema A, van Dam S, Rodenhuis S, Beijnen J. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin. Ther Drug Monit. 2005;27:756-65 pubmed
    ..This activation pathway is inhibited by thiotepa. CP is inactivated by formation of 2-dechloroethylcyclophosphamide (2DCECP)...
  41. Rick O, Bokemeyer C, Beyer J, Hartmann J, Schwella N, Kingreen D, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol. 2001;19:81-8 pubmed
    ..by one cycle of high-dose chemotherapy (HDCT) with carboplatin 500 mg/m(2) x 3, etoposide 600 mg/m(2) x 4, and thiotepa 150 to 250 mg/m(2) x 3 (CET)...
  42. Fagioli F, Biasin E, Mastrodicasa L, Sandri A, Ferrero I, Berger M, et al. High-dose thiotepa and etoposide in children with poor-prognosis brain tumors. Cancer. 2004;100:2215-21 pubmed
    ..diagnosed high-risk brain tumors and who underwent high-dose chemotherapy with triethylenethiophosphoramide (thiotepa) and etoposide in addition to autologous stem cell transplantation between May 1992 and September 2002...
  43. Huitema A, Kerbusch T, Tibben M, Rodenhuis S, Beijnen J. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother Pharmacol. 2000;46:119-27 pubmed
    Cyclophosphamide and thioTEPA are frequently used simultaneously in high-dose chemotherapy regimens...
  44. Xu Y, Hansen W, Rosenquist T, Williams D, Limp Foster M, Kelley M. Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N'-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications. J Pharmacol Exp Ther. 2001;296:825-31 pubmed
    ..N,N',N"-triethylenethiophosphoramide (thiotepa), a polyfunctional alkylating agent, is used in the treatment of breast, ovarian, and bladder carcinomas and is ..
  45. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000;356:1384-91 pubmed
    ..n=251), or three cycles of FEC at standard doses followed by high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin (CTCb), and peripheral-blood stem-cell or bone-marrow support (n=274)...
  46. Pezuk J, Valera E, Delsin L, Scrideli C, Tone L, Brassesco M. The Antiproliferative and Pro-apoptotic Effects of Methoxyamine on Pediatric Medulloblastoma Cell Lines Exposed to Ionizing Radiation and Chemotherapy. Cent Nerv Syst Agents Med Chem. 2015;16:67-72 pubmed
    ..either alone or combined with various chemotherapeutic compounds: cisplatin (CDDP), temozolomide (TMZ) and thiotepa (THIO). Additionally, cell lines were exposed to MX and treated at different ionizing radiation fractions...
  47. Ferreri A, Ciceri F, Brandes A, Montanari M, Balzarotti M, Spina M, et al. MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. Neurology. 2014;82:1370-3 pubmed publisher
    ..We report updated results at a median follow-up of 12 years of a phase II trial assessing first-line MATILDE chemotherapy and response-tailored radiotherapy in patients with primary CNS lymphomas (PCNSL)...
  48. Oh D, Chua N, Street L, Stewart D. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. Leuk Lymphoma. 2016;57:28-33 pubmed publisher
    ..The optimal HD regimen for SCNSL is unknown. Despite reports of thiotepa/busulfan-based conditioning for primary CNS lymphoma, very little data exist regarding the use of this regimen ..
  49. Joffe E, Rosenberg D, Rozovski U, Perry C, Kirgner I, Trestman S, et al. Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma. Bone Marrow Transplant. 2017;: pubmed publisher
    This study aimed to compare the real-life results of TECAM, a thiotepa-based conditioning regimen consisting of thiotepa (40?mg/m2 days -5 to -2), etoposide (200?mg/m2 days -6 to -3), cytarabine (200?mg/m2 ..
  50. Orlando L, Curigliano G, Colleoni M, Fazio N, Nole F, Martinelli G, et al. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res. 2002;22:3057-9 pubmed
    ..with repeated courses of intrathecal chemotherapy according to the following alternated weekly schedule: Day 1: Thiotepa 10 mg, methotrexate 15 mg, hydrocortisone 30 mg; Day 5: cytarabine (Ara-C) 70 mg, methotrexate 15 mg, ..
  51. VanderWalde A, Ye W, Frankel P, Asuncion D, Leong L, Luu T, et al. Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer. Biol Blood Marrow Transplant. 2012;18:1273-80 pubmed publisher
    ..In this study, patients initiated high-dose chemotherapy with STAMP-V (carboplatin, thiotepa, and cyclophosphamide), ACT (doxorubicin, paclitaxel, and cyclophosphamide), or tandem melphalan and STAMP-V...
  52. Baek H, Park H, Sung K, Lee S, Han J, Koh K, et al. Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study. J Neurooncol. 2013;114:329-38 pubmed publisher
    ..CTE (carboplatin-thiotepa-etoposide) and cyclophosphamide-melphalan (CM) regimens were used for the first and second HDCT, respectively...
  53. Skeel R, Andersen J, Tormey D, Benson A, Asbury R, Falkson G. Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone to thiotepa, doxorubicin, vinblastine, and fluoxymesterone: an Eastern Cooperative Oncology Group Study. Cancer. 1989;64:1393-9 pubmed
    ..two chemotherapy programs, dibromodulcitol, Adriamycin, vincristine, and Halotestin (fluoxymesterone) (DAVH), and thiotepa, Adriamycin, vinblastine, and Halotestin (TAVH), were chosen for comparison on the basis of reported response ..
  54. Torabifard H, Fattahi A. Mechanisms and kinetics of thiotepa and tepa hydrolysis: DFT study. J Mol Model. 2012;18:3563-76 pubmed publisher
    N,N',N?-triethylenethiophosphoramide (Thiotepa) and its oxo analogue (Tepa) as the major metabolite are trifunctional alkylating agents with a broad spectrum of antitumor activity...
  55. Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008;26:3166-75 pubmed publisher
    ..The results of this large series indicate that rituximab should be included in the current practice of PBPC autograft for DLB-CL and FL. ..
  56. Demirer T, Uysal V, Ayli M, Genc Y, Ilhan O, Koc H, et al. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation. Bone Marrow Transplant. 2003;31:755-61 pubmed
    This study was conducted to evaluate the efficacy of high-dose thiotepa, melphalan and carboplatin (TMCb) regimen in 27 patients undergoing autologous stem cell transplantation (ASCT) for metastatic breast cancer...
  57. Fay M, Shih J. Weighted logrank tests for interval censored data when assessment times depend on treatment. Stat Med. 2012;31:3760-72 pubmed publisher
    ..Simulations were performed using the interval R package. ..
  58. Weigel B, Breitfeld P, Hawkins D, Crist W, Baker K. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol. 2001;23:272-6 pubmed
    ..Clearly, there is a need for incorporating new treatment strategies for patients with high-risk RMS. ..
  59. Wang X, Ren J, Zhang J, Yan Y, Jiang N, Yu J, et al. Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). Clin Transl Oncol. 2016;18:82-7 pubmed publisher
    ..All cases were subsequently experienced 2 cycles of chemotherapy with cyclophosphamide 3 g/m(2), thiotepa 150 mg/m(2), and carboplatin AUC = 6, Q4w...
  60. Lichtman S, Budman D, Bosworth H, Allen S, Schulman P, Weiselberg L, et al. Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial. Am J Clin Oncol. 1991;14:317-21 pubmed
    ..followed by radiation therapy to the breast, and concluding with four cycles of VATH (vinblastine, Adriamycin, thiotepa, Halotesin). Twenty-seven patients were entered with an average age of 51...
  61. Miyazaki M, Miyakoshi S, Kami M, Mori M, Kishi Y, Inagawa H, et al. Systemic fusariosis after a preparative regimen including thiotepa, VP-16 and busulfan used for blood stem cell transplantation in Hodgkin's disease. Leuk Lymphoma. 2001;40:441-4 pubmed
    ..A 27-year-old man developed systemic fusarial infection following severe skin damage probably caused by high-dose thiotepa administration...